Caricamento...
Amuvatinib has cytotoxic effects against NRAS- but not BRAF-mutant melanoma
Effective targeted therapy strategies are still lacking for the 15–20% of melanoma patients whose melanomas are driven by oncogenic NRAS. We here report on the NRAS-specific behavior of amuvatinib, a kinase inhibitor with activity against c-KIT, Axl, PDGFRα and Rad51. An analysis of BRAF- and NRAS-m...
Salvato in:
| Pubblicato in: | Melanoma Res |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4384823/ https://ncbi.nlm.nih.gov/pubmed/24950457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000103 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|